FiercePharma8d
TV drug ad spending reached new heights in January, as Novartis' Pluvicto toppled AbbVie's Skyrizi for top spot
AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...
FierceBiotech4d
Boehringer widens fibrosis drug's approval path after boosting lung function in 2nd phase 3 trial
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
BioSpace4d
Boehringer Ingelheim’s Lung Fibrosis Drug Scores Second Late-Stage Win
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
CMAJ25d
People living with diabetes mellitus
Continuous glucose monitors can predict some imminent hypoglycemic episodes, allowing a proactive approach to treatment ... Boehringer Ingelheim, The CPD Network, Dexcom, e-diabete, Eli Lilly, Janssen ...
Healio16d
‘We applaud CMS’: Two more rheumatology drugs bound for Medicare price negotiation
Ofev (nintedanib, Boehringer Ingelheim) and Otezla (apremilast, Amgen) were selected for the CMS program’s new round of negotiations along with 13 other medications, including semaglutide ...